Royalty Pharma Plc (RPRX) — Cash Flow-to-Debt Ratio
Royalty Pharma Plc (RPRX) has a Cash Flow-to-Debt Ratio of 0.08x as of March 2026, meaning its operating cash flow of $760.54 Million could theoretically repay 0% of its total liabilities ($9.88 Billion) in one year. See Royalty Pharma Plc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Royalty Pharma Plc Cash Flow-to-Debt Ratio (2002–2025)
Historical debt coverage capacity for Royalty Pharma Plc across 14 annual periods. Also explore RPRX shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Royalty Pharma Plc (2002–2025)
Year-by-year debt coverage analysis for Royalty Pharma Plc. For market capitalisation and broader financial context, see Royalty Pharma Plc (RPRX) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.25x | $2.49 Billion | $9.91 Billion | ▼ -28.5% |
| 2024 | 0.35x | $2.77 Billion | $7.88 Billion | ▼ -25.9% |
| 2023 | 0.47x | $2.99 Billion | $6.30 Billion | ▲ +61.3% |
| 2022 | 0.29x | $2.14 Billion | $7.29 Billion | ▲ +6.0% |
| 2021 | 0.28x | $2.02 Billion | $7.27 Billion | ▼ -16.4% |
| 2020 | 0.33x | $2.03 Billion | $6.12 Billion | ▲ +25.7% |
| 2019 | 0.26x | $1.67 Billion | $6.31 Billion | ▲ +11.3% |
| 2018 | 0.24x | $1.62 Billion | $6.82 Billion | ▲ +15.5% |
| 2017 | 0.21x | $1.42 Billion | $6.90 Billion | ▲ +8039.6% |
| 2016 | 0.00x | $-15.58 Million | $6.02 Billion | ▲ +37.5% |
| 2015 | 0.00x | $-25.33 Million | $6.12 Billion | ▲ +100.0% |
| 2014 | -10.03x | $-29.33 Million | $2.92 Million | ▼ -148.7% |
| 2003 | 20.61x | $11.15 Million | $541.00K | ▲ +26.7% |
| 2002 | 16.27x | $8.45 Million | $519.00K | — |